Author's response to reviews

Title: Changes in Prostaglandin E2 in patients with idiopathic OAB after BoNT-A (botulinum toxin type A) treatment: is there a clinical benefit?

Authors:

Axel Hegele (hegele@med.uni-marburg.de)
Sonja Knippschild (hegele@med.uni-marburg.de)
Carsten Frohme (frohme@med.uni-marburg.de)
Jörg Hänze (joerg.haenze@med.uni-marburg.de)
Peter Olbert (olbert@med.uni-marburg.de)
Rainer Hofmann (rainer.hofmann@med.uni-marburg.de)

Version: 4 Date: 16 September 2014

Author's response to reviews: see over
To
Editor-in-Chief,

BMC Urology

Resubmission of revised manuscript entitled MS: 2086781830135106 - Changes in Prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?

Dear Editor-in-Chief,

attached please find our revised manuscript (MS: 2086781830135106). The manuscript was edited again by a natural speaker.

Based on the comments of the reviewers all points were clarified and corrected – marked cursive in the manuscript.

Reviewer #1 (Antonio A Cicione)

Major Compulsory Revisions

Ad 1) a table with the baseline features is added (table 1)

Ad 2) wash out time and use of other medications is clarified in the method section “patients”.

Ad 3) the study limits (i.e. small sample size) is reported in the discussion part.

Discretionary Revisions

Ad 1) a table was added summarizing the results

Ad 2) the definitions are added in the method section “Inclusion criteria”.

Universitätsklinikum GI und MR GmbH, Baldingerstr., 35033 Marburg

Klinik für Urologie und Kinderurologie
Direktor: Prof. Dr. med. R. Hofmann
Standort Marburg
Baldingerstraße, 35033 Marburg-Germany

Prof. Dr. med. Axel Hegele
Geschäftsführender Oberarzt
Medikamentöse Tumortherapie
Telefon: 0049(0)6421) 5862575
E-Mail: hegele@med.uni-marburg.de

Allgemeines Sekretariat:
Telefon: (06421) 58 – 62513
Telefon: (06421) 58 – 64475 (stat. Aufnahmen)
Telefax: (06421) 58 – 65590

Urologische Poliklinik:
Telefon: (06421) 58 – 62558
Telefax: (06421) 58 – 62482
Datum: 16.09.2014
Reviewer #2 (Maria Furlan)

Major Revisions

Ad 1) the efficacy outcomes are clarified in the method section (“therapeutic success”) concerning to ICS definition of OAB. After correct outlining of the outcome parameters the results are coherent.

Ad 2) The population of the study is described more detailed. Additionally the time period is specified. Inclusion criteria were also described in detail and clearly defined.

Ad 3) Data about patients were corrected and tables are added (see table 1/2).

Minor Essential Revisions

Ad 5) used statistical tests are added to the abstract (method section)

Ad 6) number was corrected

Ad 7) Patients were grouped like suggested and a table with the results concerning the different groups is added.

Ad 8) was corrected

Ad 9) complete informations are added

Ad 10) was corrected

Ad 11) the p-values are added

Ad 12) reference number “6” is added in the reference section

Ad 13) follow-up period is added for each group.

Ad 14) patients often come from afar to our department for therapy. So only about 50% of the patients returned to the control date as arranged. This unfortunately reflects “real life” conditions in treating and controlling patients at a university hospital with a large catchment area in Germany – but we are working on patients motivation to improve number of controlled patients in following investigations.

Ad 15+16) figure 3 and its legend are corrected inclusively x- and y-coordinates.

After complete revision according to the suggestions of the reviewers we hope, that the manuscript is now acceptable for publication.

If there are any questions please do not hesitate to contact me.

With best regards

Yours sincerely

(Prof. Dr. A. Hegele)